Status:
COMPLETED
Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease
Lead Sponsor:
Wuhan General Hospital of Guangzhou Military Command
Conditions:
Type 2 Diabetes
Coronary Artery Disease
Eligibility:
All Genders
40-70 years
Phase:
PHASE4
Brief Summary
Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD). Most of the attention in treating CAD in type 2 diabetes is und...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- CAD
- Left ventricular hypertrophy
- HbA1c below 7.0%
- blood pressure \<130/80 mmHg
Exclusion
- Patients were excluded if they were currently alpha-lipoic acid for one year, had a previous adverse reaction to alpha-lipoic acid.
- hey were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
- Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women.
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2015
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT01877590
Start Date
November 1 2013
End Date
July 1 2015
Last Update
August 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan General Hospital
Wuhan, Hubei, China, 430070